Historical Valuation
60 Degrees Pharmaceuticals Inc (SXTP) is now in the Fair zone, suggesting that its current forward PS ratio of 1.47 is considered Fairly compared with the five-year average of -0.88. The fair price of 60 Degrees Pharmaceuticals Inc (SXTP) is between 0.49 to 0.84 according to relative valuation methord.
Relative Value
Fair Zone
0.49-0.84
Current Price：0.52
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
60 Degrees Pharmaceuticals Inc (SXTP) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of -0.61 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of -0.61, the current P/B ratio is about -100.00% higher. 60 Degrees Pharmaceuticals Inc (SXTP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -160.47%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -160.47% , the current FCF yield is about -100.00% lower.
P/B
Median3y
-0.61
Median5y
-0.61
FCF Yield
Median3y
-160.47
Median5y
-160.47
Competitors Valuation Multiple
AI Analysis for SXTP
The average P/S ratio for SXTP competitors is 0.72, providing a benchmark for relative valuation. 60 Degrees Pharmaceuticals Inc Corp (SXTP.O) exhibits a P/S ratio of 1.47, which is 104.98% above the industry average. Given its robust revenue growth of 75.42%, this premium appears sustainable.
Performance Decomposition
AI Analysis for SXTP
1Y
3Y
5Y
Market capitalization of SXTP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SXTP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SXTP currently overvalued or undervalued?
60 Degrees Pharmaceuticals Inc (SXTP) is now in the Fair zone, suggesting that its current forward PS ratio of 1.47 is considered Fairly compared with the five-year average of -0.88. The fair price of 60 Degrees Pharmaceuticals Inc (SXTP) is between 0.49 to 0.84 according to relative valuation methord.
What is 60 Degrees Pharmaceuticals Inc (SXTP) fair value?
SXTP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of 60 Degrees Pharmaceuticals Inc (SXTP) is between 0.49 to 0.84 according to relative valuation methord.
How does SXTP's valuation metrics compare to the industry average?
The average P/S ratio for SXTP's competitors is 0.72, providing a benchmark for relative valuation. 60 Degrees Pharmaceuticals Inc Corp (SXTP) exhibits a P/S ratio of 1.47, which is 104.98% above the industry average. Given its robust revenue growth of 75.42%, this premium appears sustainable.
What is the current P/B ratio for 60 Degrees Pharmaceuticals Inc (SXTP) as of Jan 09 2026?
As of Jan 09 2026, 60 Degrees Pharmaceuticals Inc (SXTP) has a P/B ratio of 0.00. This indicates that the market values SXTP at 0.00 times its book value.
What is the current FCF Yield for 60 Degrees Pharmaceuticals Inc (SXTP) as of Jan 09 2026?
As of Jan 09 2026, 60 Degrees Pharmaceuticals Inc (SXTP) has a FCF Yield of 0.00%. This means that for every dollar of 60 Degrees Pharmaceuticals Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP) as of Jan 09 2026?
As of Jan 09 2026, 60 Degrees Pharmaceuticals Inc (SXTP) has a Forward P/E ratio of -0.14. This means the market is willing to pay $-0.14 for every dollar of 60 Degrees Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for 60 Degrees Pharmaceuticals Inc (SXTP) as of Jan 09 2026?
As of Jan 09 2026, 60 Degrees Pharmaceuticals Inc (SXTP) has a Forward P/S ratio of 1.47. This means the market is valuing SXTP at $1.47 for every dollar of expected revenue over the next 12 months.